Arix Bioscience and Shield Therapeutics
Episode 1721, Jan 27, 2020, 12:34 PM
Arix Bioscience #ARIX explain why they co-founded Quench Bio and took part in its $50m series A financing round. Shield Therapeutics #STX provides an update outlining their progress during 2019 which included the FDA approval of their lead product, Feraccru®/Accrufer®.
On the Vox Markets Podcast Today: 27th January 2020
Jonathan Tobin Investment Director at Arix Bioscience #ARIX explains why they co-founded Quench Bio took part in its $50m series A financing round.
Tim Watts, CFO of Shield Therapeutics #STX provides an update outlining their progress during 2019 which included the FDA approval of their lead product, Feraccru®/Accrufer®.
(Interview starts at 11 minutes 19 seconds)
Plus the Top 5 Most Followed Companies & the Top 5 Most Liked RNS’s on Vox Markets in the last 24 hours.
Vox Markets is revolutionising the way companies engage with shareholders and the stock market at large. By aggregating IR and digital content onto one secure and compliant platform, Vox Markets has established itself as the go-to resource for the investment community.
#VoxMarkets #StockMarket #LivePrices #StockMarketNews #Money #Investing #Investments #Finance #Business #Podcast